Duke Singapore School, Inviragen to Work on Dengue Vaccine
This article is for subscribers only.
Duke University’s Singapore medical school agreed to work with closely held Inviragen Inc. to develop a vaccine against dengue fever, joining Sanofi Aventis SA in the quest for a shot against the deadly virus.
The Duke-National University of Singapore Graduate Medical School signed a memorandum of understanding with Fort Collins, Colorado-based Inviragen to “better understand how emerging infectious diseases are transmitted and how transmission can be prevented,” the two organizations said in a statement today.